Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BriaCell Therapeutics ( (TSE:BCT) ) has issued an update.
On January 15, 2026, BriaCell Therapeutics Corp. closed a roughly $30 million best-efforts public offering comprising 4,327,530 common units and 1,039,196 pre-funded units, each unit including either a common share or pre-funded warrant plus a warrant to purchase an additional common share, with net proceeds earmarked for working capital, general corporate purposes and advancement of its business objectives. As part of the transaction, which followed the SEC’s January 13, 2026 effectiveness of the company’s registration statements, the warrants began trading on the Nasdaq Capital Market under the symbol BCTXL on January 14, 2026, placement agent ThinkEquity received a 6.25% cash fee and separate placement agent warrants, and BriaCell appointed Computershare as warrant transfer agent, collectively strengthening the company’s capital position to support its ongoing cancer immunotherapy programs.
The most recent analyst rating on (TSE:BCT) stock is a Sell with a C$6.50 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn with likely ongoing financing needs). Technicals are mixed with some shorter-term strength but negative MACD and a price still far below the 200-day average. Valuation contributes limited support due to a negative P/E and no dividend yield.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care, with its shares listed on Nasdaq and the Toronto Stock Exchange, targeting oncology indications through advanced immune-based treatments.
Average Trading Volume: 10,819
Technical Sentiment Signal: Sell
Current Market Cap: C$12.7M
For detailed information about BCT stock, go to TipRanks’ Stock Analysis page.